Generic Kaletra Availability
KALETRA (lopinavir; ritonavir - capsule;oral)
Approval date: September 15, 2000
Strength(s): 133.3MG;33.3MG (discontinued)
KALETRA (lopinavir; ritonavir - solution;oral)
KALETRA (lopinavir; ritonavir - tablet;oral)
Approval date: October 28, 2005
Strength(s): 200MG;50MG [RLD]
Approval date: November 9, 2007
Strength(s): 100MG;25MG [RLD]
Has a generic version of Kaletra been approved?
Yes. The following products are equivalent to Kaletra:
Manufacturer: LANNETT CO INC
Approval date: December 27, 2016
Strength(s): 80MG/ML;20MG/ML [AA]
Note: No generic formulation of the following products are available.
- lopinavir; ritonavir - capsule;oral
- lopinavir; ritonavir - tablet;oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kaletra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
More about Kaletra (lopinavir / ritonavir)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 3 Reviews
- Drug class: protease inhibitors
- FDA Alerts (4)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AA||Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.